Biogen Pays $850M for Felzartamab China Rights, Eyes 14.6% Market Share
Biogen will pay up to $850 million for exclusive Greater China rights to TJ Biopharma’s anti-CD38 immunotherapy felzartamab and assume its submitted BLA for R/R MM. Felzartamab’s 1.5-hour infusion and production at Hangzhou could help Biogen capture 14.6% of China’s $458 million MM market by 2029 versus Darzalex.
1. Deal Terms and BLA Control
Biogen will pay up to $850 million to TJ Biopharma for exclusive Greater China rights to felzartamab and will assume control of the submitted biologics licence application for relapsed and refractory multiple myeloma with China’s regulator.
2. Administration and Clinical Profile
Felzartamab has shown comparable efficacy and safety to Darzalex when used alongside dexamethasone and lenalidomide, and its 1.5-hour infusion significantly reduces clinic time versus Darzalex’s up to seven-hour intravenous sessions.
3. Competitive Landscape
Janssen’s Darzalex holds 87.5% of global anti-CD38 market share with $7.1 billion in 2025 sales, while its Faspro subcutaneous formulation under trial in China offers a 3–5 minute administration and potential home use.
4. China Market Forecast and Strategy
Manufacturing at TJ Biopharma’s Hangzhou GMP facility leverages government incentives for domestic production, positioning Biogen to target roughly 14.6% of China’s $458 million multiple myeloma market by 2029.